Iovance Biotherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Iovance Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Iovance Biotherapeutics Inc Strategy Report
- Understand Iovance Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Iovance Biotherapeutics Inc (Iovance) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology for the treatment of cancer. TIL consist of a heterogeneous population of T cells that can distinguish a wide range of cancer-specific mutations and can overcome tumor escape mechanisms.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Iovance R&D activities are focused on development of immunotherapies for the treatment of metastatic melanoma, squamous cell carcinoma of the head and neck, cervical carcinoma, and other solid tumor indications. The company operates a research laboratory in Tampa, Florida, the US. In FY2022, the company spent US$294.8 million towards its R&D activities, which grew 13.8% YoY. As of December 31, 2022, the company employed 379 personnel in R&D activities. The company owns several granted patents and pending patent applications in the fields of TIL therapy, MIL therapy, PBL therapy, TIL, MIL and PBL manufacturing processes and expansion methods. It owns more than 60 granted US and international patents related to TIL therapy. Iovance seeks to work in partnerships with universities, government and academic research institutions, corporate partners to develop and commercialize its products. Its research partnerships include National Institute of Health/ National Cancer Institute; Moffitt Cancer Center; and MD Anderson Cancer Center; and Yale University, among others.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer